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Abstract
The healthcare sector in the U.S. is complex and is also a large sector that generates
about 20% of the country’s gross domestic product. Healthcare analytics has been used
by researchers and practitioners to better understand the industry. In this paper, we
examine and demonstrate the use of Beta regression models to study the utilization
of brand name drugs in the U.S. to understand the variability of brand name drug
utilization across different areas. The models are fitted to public datasets obtained
from the Medicare & Medicaid Services and the Internal Revenue Service. Integrated
Nested Laplace Approximation (INLA) is used to perform the inference. The numerical
results show that Beta regression models can fit the brand name drug claim rates well
and including spatial dependence improves the performance of the Beta regression
models. Such models can be used to reflect the effect of prescription drug utilization
when updating an insured’s health risk in a risk scoring model.
Keywords: Beta regression, healthcare analytics, random effects, spatial modeling,
1 Introduction
In the pharmaceutical industry, a brand name drug is a prescription drug that is developed
and patented by a company. The patent gives the company a period of market exclusivity,
during which the company sells the brand name drug at a significantly high price. For
more information about drug pricing, readers are referred to Schoonveld (2015). When the
patent expires, generic versions of the brand name drug are marketed at lower prices by
other companies. Generally, most states allow pharmacists to substitute brand name drugs
with generic versions, unless otherwise directed by physicians. Nevertheless, according to
the Association for Accessible Medicines (AAM) (Klinger, 2017), the generics account for
89% of prescriptions dispensed but only 26% of total drug costs in the U.S. Recent annual
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prescription spending in the United States has been on the rise. According to the NHE
(National Health Expenditure) fact sheet 1, prescription drug spending in the U.S. increased
2.5% to $335.0 billion in 2018, faster than the 1.4% growth in 2017.
This large disparity in the costs between brand name and generic drugs motivated us to
investigate for the presence of feature variables, e.g., location, income, demographics, that
drive the decision to choose one type over the other. It is also our intent to prescribe a model
that health insurers can replicate to reflect these decision drivers into a risk adjustment
program (Duncan, 2011), a mechanism widely popular for assessing the health risk of an
insured (Hileman et al., 2016). This mechanism is an umbrella of commercially designed risk
assessment models that are sometimes called risk scoring models. While models do vary,
they share a common objective of predicting the health care cost per member per year using
prior year’s medical utilization and expenditures as well as additional risk factors such as
location and demographic.
The decision to prescribe/purchase generic or brand name drugs has been studied before.
Brinberg and Cummings (1984) used two behavioral intension models to examine the deci-
sion to purchase generic prescription drugs and found several differences between individuals
who intent to purchase generic prescription drugs with those who do not. For example, non-
intenders believed it was less likely that generic drugs were a safe product than intenders.
Hamann et al. (2013) studied psychiatrists’ decision making between generic and branded
antipsychotics and found that psychiatrists were more likely to choose branded drugs when
imagining choosing the drug for themselves. Hassali et al. (2014) reviewed experiences of im-
plementing generic medicine policy in eight countries, including the U.S. The review indicates
that pharmacists play an essential role in promoting generic medicines as they substituted
83.8% of prescriptions that allowed substitution and that generic prescribing is still not com-
mon practice in the U.S. because many physicians have negative perceptions about generic
medicines and lack in-depth knowledge about the bioequivalence concept applied in the U.S.
Kesselheim et al. (2016) studied variations in patients’ perceptions and use of generic drugs
based on a national survey and found a substantial shift that more patients have positive
views of generic drugs.
In the aforementioned work, Brinberg and Cummings (1984), Hamann et al. (2013),
and Kesselheim et al. (2016) used survey data to study the behavior of the patients and
physicians. The review conducted by Hassali et al. (2014) was based on literature search
using several electronic databases and search engines such as ISI ( Institute for Scientific
Information) Web of Knowledge and Google. Public pharmaceutical drug utilization data
have not been used to study the factors driving the decision of choosing one type over the
other.
In this paper, we investigate the rates of brand name drug claims in the U.S. In particular,
we investigate the variations of the brand name drug claims rates in different areas of the
U.S. Our study supplements the aforementioned studies based on survey data. Since rates
are values in the interval (0, 1), the Beta regression model (Ferrari and Cribari-Neto, 2004)
is most suitable where covariates can be introduced to account for heterogeneity.
The remaining part of the paper is organized as follows. In Section 2, we review some
1https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-
Reports/NationalHealthExpendData/NHE-Fact-Sheet. Accessed on July 6, 2020.
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academic work related to health insurance. In Section 3, we describe the data used in our
study. In particular, we describe how the data is processed before models are fitted. In
Section 4, we present four Beta regression models for fitting the data. In Section 5, we
provide numerical results of the proposed Beta regression models. In Section 6, we conclude
the paper with some remarks.
2 Related work
Healthcare is an important practicing area of actuaries due to the existence of health insur-
ance. In this section, we review some work that is related to health insurance analytics.
Early work includes Bolnick (2004), Petertil (2005), and Bachler et al. (2006). Bolnick
(2004) proposed a framework for long-term healthcare cost projections by incorporating key
healthcare cost drivers such as life expectancy, biological morbidity, and economic morbidity.
Using the framework, Bolnick (2004) considered various plausible future scenarios that en-
compass a reasonable range of healthcare cost outcomes. Petertil (2005) studied the relative
significance of aging as a driver of healthcare cost beyond age fifty and used Medicare data
to draw general conclusions that utilization and cost differ by age. Bachler et al. (2006)
studied the impact of chronic and nonchronic insured members on cost trends and found
that classification of chronic members can affect the trends significantly.
Recently, there has been a lot more studies on healthcare analytics than ten years ago.
Duncan (2011) devoted a book to healthcare analytics for actuaries. In particular, this book
covers the essentials of health risk and case studies on the use of predictive modeling in risk
adjustment. For example, Chapter 14 of this book discusses the risk adjustment method
used by the Centers for Medicare and Medicaid Services (CMS). Frees et al. (2011) extended
the standard two-part model to predict the frequency and amount of healthcare expenditures
and used the data from the Medical Expenditure Panel Survey (MEPS) to calibrate and test
the model. Shi and Zhang (2013) built a game-theoretic model based on copulas to study
the effect of managed care on healthcare utilization compared to traditional fee-for-service
plans in private health insurance market.
Getzen (2016) developed a method to evaluate projections of future medical spending
used by the U.S. Medicare and Medicaid programs and found that the recent set of projec-
tions (1998–2010) is more accurate than the older set of projections (1986–1995) because
the recent projections incorporate lagged macroeconomic effects. Duncan et al. (2016) in-
vestigated several statistical techniques (e.g., Lasso GLM, multivariate adaptive regression
splines, random forests, decision trees, and boosted trees) for modeling future healthcare
costs and found that the traditional regression approach does not perform well.
Huang et al. (2017) compared different models and model selection methods for health
costs in Episode Treatment Groups (ETGs) and found that random forest feature selection
is preferable in terms of efficiency and accuracy. Richardson and Hartman (2018) proposed a
Bayesian nonparametric regression model for predicting healthcare claims. Their numerical
results show that the Bayesian nonparametric model outperforms standard linear regression
and generalized Beta regression in terms of predictive accuracy. Brockett et al. (2018)
investigated the use of Data Envelopment Analysis (DEA), which is a method developed in
management science to measure relative efficiency of organizations, to assess the potential
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savings of Medicare. Their analysis shows that Medicare Advantage plans are more efficient
in reducing health expenditures than the original Medicare. In Brockett et al. (2019), the
authors used linear regression models to estimate the effect of medical loss ratio (MLR) and
efficiency on the quality of care for the Medicaid managed care plans. The results show that
the effect of medical services efficiency on the quality of care is insignificant. Kan et al.
(2019) explored the use of machine learning techniques for risk adjustment and found that
penalized regression performs better than ordinary least squares in predicting healthcare
costs.
Our work presented in this paper is relative to healthcare analytics but is different from
the work mentioned above. In particular, our work examined Beta regression model with
spatial dependence to model the percentages of bran name drug claims. The methods and
findings of this paper can be used by practitioners in their risk modeling and adjustment.
3 Description of the Data
We use a public dataset called the Part D Prescriber Public Use File (PUF) from the Centers
for Medicare & Medicaid Services (CMS) and another public dataset called Individual Income
Tax Statistics from the IRS (Internal Revenue Service).
The data in the Part D Prescriber PUF cover calendar years 2013 through 2016 and
contain information on prescription drug events (PDEs) incurred by Medicare beneficiaries
with a Part D prescription drug plan. The data consist of a detailed data file and two
summary tables. The “Part D Prescriber Summary Table” contains overall drug utilization,
drug costs, and beneficiary counts organized by National Provider Identifier (NPI). In this
paper, we use the 2016 Part D Prescriber Summary Table, which contains 1,131,550 records
and 84 variables 2. The Part D Prescriber Summary table contains information about the
brand and generic drug claims at the provider level. Other information includes the zip code
of providers, the count of beneficiaries, the average age of beneficiaries, and the average risk
score of beneficiaries.
In this paper, our interest is on studying variations of the brand name drug claims rates
in different areas of the U.S. To that end, we need to aggregate the data to different areas.
However, the data can be aggregated to different levels: the state level, the zip code level,
or some customized level between the state level and the zip code level. On the one hand,
aggregating the data to the state level is not desirable for the following reasons:
• The brand name drug claim rate exhibits variations within individual states.
• The U.S. has only 50 states and aggregating the data to the state level produces only
50 data points.
On the other hand, aggregating the data to the zip code level is also not desirable:
2The file name is PartD Prescriber PUF NPI 16.txt and it is available from https://www.cms.gov/
Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-
Charge-Data/PartD2016. Accessed on Jan 20, 2020.
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• The dataset contains about 20,000 different zip codes. Aggregating the data to the
zip code level will produce about 20,000 data points. This will cause challenges in
modeling the spatial effects as a large number of sites requires lots of parameters.
• Some zip codes do not correspond to geographical areas but large volume customers
or post office boxes.
• Aggregating the data to the zip level produces highly volatile brand name drug claims
rates. That is, the rates are highly volatile between zip codes.
As a result, we decide to aggregate the data to some customized level between the state level
and the zip code level.
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Figure 1: A mesh of the 48 contiguous states with 530 triangles.
To aggregate the data to a customized level, we first need to split the U.S. land into small
areas, i.e., create a mesh of the U.S. land. This can be done conveniently by using the R
function inla.mesh.2d from the INLA package. Figure 1 shows a mesh of the 48 contiguous
states of the U.S. that consists of 530 triangles. Aggregating the data to the 530 triangular
areas will produce a dataset with about 530 data points. This is computationally reasonable
for modeling spatial effects.
Aggregating the data to the triangles shown in Figure 1 is done as follows. First, we
obtain the longitudes and the latitudes of zip codes from the R package noncensus, which
contains regional information and demographic data determined by the U.S. Census Bureau.
Note that each zip code is associated with a longitude and a latitude. Second, we determine
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the triangles to which the zip codes belong by using the longitudes and the latitudes. Finally,
we aggregate the data based on the indices of the triangles.
The Part D Summary Table contains average ages and average risk scores of the bene-
ficiaries. The average risk scores are average HCC (Hierarchical Condition Category) risk
scores, which estimate how beneficiaries’ FFS (Fee-For-Service) spending will compare to
the overall average of the entire Medicare population. Before aggregating the data, we con-
vert average ages and average risk scores to total ages and total risk scores by multiplying
the average numbers with the count of beneficiaries. After aggregation is done, we convert
total ages and total risk scores to average ages and average risk scores by dividing the total
number by the aggregated count of beneficiaries. The Part D Summary Table also contains
missing values. We remove missing values before aggregating the data.
25
30
35
40
45
50
−120 −100 −80
Longitude
La
tit
ud
e
0.2
0.3
0.4
brandrate
(a)
0
10
20
30
40
0.2 0.3 0.4
Brandrate
Fr
eq
ue
nc
y
(b)
Figure 2: Distributions of the brand name drug claim rates. White triangles mean that data
are not available in these areas.
Figure 2(a) shows the distribution of the brand name drug claim rates in different tri-
angular areas. From the figure, we see that 19 triangular areas do not have the data. As a
result, the aggregated dataset contains 511 observations. From the figure, we also see that
some triangles in the middle are light red. This suggests that modeling the spatial effects
may improve the fitting of Beta regression models to the data.
Table 1: Summary statistics of the Part D data.
Min 1st Q Median Mean 3rd Q Max
brandrate 0.1253 0.1784 0.1886 0.1890 0.1986 0.4118
avgage 65.79 70.06 70.89 70.98 71.87 80.00
avgscore 0.9129 1.2102 1.3240 1.3170 1.4199 1.8166
Table 1 shows the summary statistics of the aggregated data. From the table, we see
that the brand name drug claim rate varies from 12.53% to 41.18% among the 511 areas.
The range of the average age of beneficiaries is from 65.79 to 80. The average risk score has
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a range of 0.9129 to 1.8166. The median and mean values indicate that these variables are
pretty symmetrical.
Another data source we use in our study is the 2016 individual income tax statistics
by zip codes 3. This dataset contains 29,874 records, each of which is described by 144
variables. It contains information about the number of returns and the amount of returns
in different categories. For example, it contains the number of returns with unemployment
compensation and the unemployment compensation amount. The return counts and amounts
are aggregated to the zip code level. Although this datast does not contain all information
about an area, it does provide some demographic and economic information, which might
be useful for explaining the variation of the brand name drug claim rate. For example, the
number of returns from an area is related to the population of the area.
We aggregate the tax data to the 530 triangular areas in the same way as we aggregate
the Part D data. After aggregating the data, we divide the total dollar amount of an area
by the corresponding number of returns to get the average dollar amount of the area. The
total number of returns and the average amounts in different categories are used in the data
analysis. Since this dataset has 144 variables, we do not show the summary statistics of
these variables here.
4 Models
In this section, we describe some Beta regression models. In particular, we present four
models: the basic Beta regression model, the Beta regression model with random effects, the
Beta-Besag model, and the Beta-BYM model.
The density function of the Beta distribution is typically defined as (Klugman et al.,
2012):
f(y; p, q) =
Γ(p+ q)
Γ(p)Γ(q)
yp−1(1− y)q−1, 0 < y < 1, (1)
where p > 0 and q > 0 are shape parameters. The Beta distribution defined in Equation (1)
has been reparameterized by using its mean and dispersion as parameters.
f(y;µ, φ) =
Γ(φ)
Γ(µφ)Γ((1− µ)φ)y
µφ−1(1− y)(1−µ)φ−1, 0 < y < 1, (2)
where 0 < µ < 1 and φ > 0. The shape parameters can be obtained from the mean and the
dispersion as follows: p = φµ and q = φ(1− µ).
The basic Beta regression model is described as follows. Suppose that we have n obser-
vations. For i = 1, 2, . . . , n, let xi = (xi1, xi2, . . . , xik)
T and yi be the vector of k regressors
and the response in the ith case, respectively. The responses y1, y2, . . . , yn are assumed to
form a random sample such as
yi ∼ Beta(µi, φ).
The mean µi is linked to the regressors as follows:
g(µi) = ηi = x
T
i β, (3)
3The file name is 16zpallagi.csv and it is available from https://www.irs.gov/statistics/soi-
tax-stats-individual-income-tax-statistics-2016-zip-code-data-soi. Accessed on Jan 12, 2020.
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where g(·) is the link function and β = (β1, β2, . . . , βk)T is the vector of regression coefficients.
The variance of yi can be estimated as
Var(yi) =
µi(1− µi)
1 + φ
. (4)
Random effects models are commonly used to analyze areal or spatial data. For example,
Tufvesson et al. (2019) applied random effects models to model car insurance data with
geographical locations of the policyholders. There are two types of random effects models:
unstructured and structured. Unstructured random effects models assume independence of
the random effects, while structured random effects models allow for spatial dependence.
The second model we consider is a Beta regression model with a single random effect. In
this model, a random effect is introduced to the linear predictor as follows:
g(µi) = ηi = x
T
i β + vi, (5)
where vi are i.i.d Gaussian noise, i.e.,
vi ∼ N
(
0,
1
ψ1
)
, (6)
where ψ1 is a precision parameter. This model can help to control for unobserved hetero-
geneity when the heterogeneity is not correlated with independent variables. The basic Beta
regression model assumes that the heterogeneity is correlated with independent variables.
The third model we consider is the Besag model, which introduces a structured random
effect to the linear predictor:
g(µi) = ηi = x
T
i β + ui, (7)
where uis follow a CAR(1) model, i.e., an order-1 conditional autoregressive model (Besag
and Kooperberg, 1995). Building a CAR model requires a neighborhood graph, which tells
which areas are neighbors to each other. Figure 3 shows a neighborhood graph where areas
that are neighbors are connected by blue lines. In our models, we assume that triangles that
share a vertex or a side are neighbors to each other.
Given a neighborhood graph, the CAR(1) model assumes that the random effect in an
area is related to the random effects in the area’s neighbors through a conditional Gaussian
distribution:
ui|{uj : j ∈ Ai} ∼ N
(
1
|Ai|
∑
j∈Ai
uj,
1
ψ2|Aj|
)
, (8)
where Ai is the set of indices of neighbors of the ith area, |Ai| denotes the number of elements
in Ai, and ψ2 is a precision parameter. Note that the CAR(1) model can be written as a
multivariate Gaussian model for u = (u1, u2, . . . , un) (Besag and Kooperberg, 1995; Wang
et al., 2018):
u ∼ N
(
0,
1
ψ2
Q−1
)
, (9)
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Figure 3: The neighborhood graph used to model spatial effects.
where Q is a highly sparse matrix defined by
Qij =

|Ai|, if i = j,
−1, if j ∈ Ai,
0, otherwise.
The fourth model is the BYM (Besag-York-Mollie´) model, which combines an unstruc-
tured random effect and a structured random effect (Besag et al., 1991):
g(µi) = ηi = x
T
i β + ui + vi, (10)
where uis are modeled by a CAR(1) model as specified in Equation (8) and vis are i.i.d
Gaussian noise as specified in Equation (6). The structured effects u model the spatial
effect. The unstructured effects v = (v1, v2, . . . , vn) are used to model additional random
variations that are not explained by geographical locations. Between the two effects u and
v, a larger effect of v in the model means that less exchange of information between areas
is allowed. The relative strengths of the unstructured effects v and the structured effects u
are controlled by the two hyperparameters ψ1 and ψ2, respectively.
Table 2 summarizes the four Beta regression models described above. The first two models
do not consider spatial dependence, while the last two models allow for spatial dependence.
There are several choices of the link function (Ferrari and Cribari-Neto, 2004):
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Table 2: Linear predictors of the four models.
Model name Linear predictor
BetaReg Equation (3)
BetaRE Equation (5)
BetaBesag Equation (7)
BetaBYM Equation (10)
• the logit link: g(µ) = log µ
1− µ ;
• the probit link: g(µ) = Φ−1(µ), where Φ(·) is the standard normal distribution function;
• the log-log link: g(µ) = − log(− log(µ));
• the complimentary log-log link: g(µ) = log(− log(1− µ));
• the Cauchy link: g(µ) = tan(pi(µ− 0.5)).
Figure 4 shows the plots of these link functions. The logit, probit, and Cauhy link function
are symmetric around the point (0.5, 0). The other two link functions are not symmetric
around the point.
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Figure 4: Some link functions for Beta regression models.
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5 Results
In this section, we present the results of fitting the four Beta regression models (see Table
2) to the brand drug claim data.
5.1 Data transformation
Before we fit the models, we transform the covariates by using the YeoJohnson transforma-
tion introduced by Yeo and Johnson (2000). The purpose of transforming the covariates is
to reduce their magnitudes for the convenience of modeling fitting. The YeoJohnson trans-
formation is similar to the power transformation but can handle zero and negative values.
In this transformation, a value x is transformed as follows:
x∗ =
{
log(1 + x), if x ≥ 0,
− log(1− x), if x < 0. (11)
We transform all covariates except for the average risk score before fitting the models.
After transforming the data, we split the dataset into two sets: one for fitting the models
and one for validating the models. We use 80% of the data for fitting and the remaining
20% for evaluation. Figure 5 shows the distribution of the brand name drug claim rates for
the training set and the test set.
25
30
35
40
45
50
−120 −100 −80
Longitude
La
tit
ud
e
0.2
0.3
0.4
brandrate
(a) The training set.
25
30
35
40
45
50
−120 −100 −80
Longitude
La
tit
ud
e
0.2
0.3
0.4
brandrate
(b) The test set.
Figure 5: The distribution of the brand name drug claim rates for the training and test sets.
5.2 Selection of covariates
The data contain 145 covariates, which include 143 from the individual tax income file and 2
(i.e., avgage and avgscore) from the Part D Summary Table. Including all these covariates
in the models causes the parameter identification problem because many of these covariates
are highly correlated.
To select covariates for fitting the models, we use the lasso regularized generalized linear
models (GLMs), which have been implemented in the R package glmnet (Friedman et al.,
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2010). Tufvesson et al. (2019) used this method to select covariates. However, the package
glmnet does not support Beta regression models. To circumvent this problem, we first create
a new binary response variable by comparing the brand name drug claim rates to the average
rate. If a rate is above the average, then the corresponding response value is 1. Otherwise,
the response value is 0. Then use lasso regularized logistic regression that is supported by
glmnet to select covariates. We assume that the covariates that help to separate high and
lower rates can also serve as useful predictors.
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Figure 6: Results from a cross-valuation run of the lasso regularized logistic GLM based on
the training set.
Figure 6 shows the results from a cross-validation run of the lasso regularized logistic
GLM with different penalties λ. In the figure, the left dashed vertical line corresponds to
the penalty λmin that minimizes the cross-validation error. The second dashed vertical line
corresponds to the smallest penalty λ1se with the error that is within one standard deviation
of the minimal error. We use the model with the penalty λ1se to select covariates. This gives
us 12 covariates, which are described in Table 3. These 12 selected covariates are used to fit
the Beta regression models.
Figure 7 shows a correlation plot of the response variable and the covariates. From the
figure, we see that many of these variables are positively correlated. The variable A11070 is
negatively correlated with a few other variables.
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Table 3: Descripton of the selected covariates.
Covariate Description
avgscore Average risk score
VITA Number of volunteer income tax assistance (VITA) prepared returns
A00900 Business or professional net income (less loss) amount
A02300 Unemployment compensation amount
A03150 Individual retirement arrangement payments amount
A03230 Tuition and fees deduction amount
A18450 State and local general sales tax amount
A18800 Personal property taxes amount
A07230 Nonrefundable education credit amount
A85770 Total premium tax credit amount
A11070 Additional child tax credit amount
A11902 Overpayments refunded amount
l
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Figure 7: Correlation of the selected covariates and the response variable.
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5.3 Fitting of the models
Bayesian methods have been used to analyze spatial data for about twenty years since year
2000 with the advent of Markov Chain Monte Carlo (MCMC) simulative methods (Blan-
giardo and Cameletti, 2015). In fact, the advent of MCMC has allowed researchers to use
Bayesian methods to develop complex models on large datasets. However, one major draw-
back of MCMC methods is that they are computationally demanding, especially for large
datasets. INLA (Integrated Nested Laplace Approximation) is as an alternative to MCMC
for Bayesian inference (Rue and Held, 2005; Rue et al., 2009). A major advantage of INLA
is that it is a deterministic algorithm and is capable of producing accurate and fast results.
Since INLA was embedded into R through the R package INLA, it has become popular among
researchers and practitioners. For example, Tufvesson et al. (2019) used INLA to model car
insurance frequency and severity. In this paper, we use the R package INLA (Blangiardo and
Cameletti, 2015; Wang et al., 2018) to fit the four Beta regression models.
The four models described in Section 4 can be formulated as Bayesian hierarchical models.
For example, the BetaBYM model can be expressed as
yi|ηi ∼ Beta(g−1(ηi), φ), (12a)
ηi = x
T
i β + ui + vi, (12b)
vi|ψ1 ∼ N
(
0, ψ−11
)
, (12c)
u|ψ2 ∼ N
(
0, ψ−12 Q
−1) , (12d)
ψ ∼ pi(ψ), (12e)
where pi(·) denotes a prior distribution for the two hyperparameters ψ1 and ψ2. Common
choices for the prior distribution of ψ include independent gamma distributions. In this
paper, we use the default priors in INLA.
5.4 Model selection and validation
The deviance information criterion (DIC) of Spiegelhalter et al. (2002) and the Watan-
abe Akaike information criterion (WAIC) of Watanabe (2010) are commonly used to select
Bayesian models. The DIC is motivated by the Akaike information criterion (AIC) and is
defined as
DIC = E[D(θ)] + pD = D(E[θ]) + 2pD, (13)
where
D(θ) = −2 log(p(y|θ))
is the deviance of the model and pD denotes the effective number of parameters that is
defined as
pD = E[D(θ)]−D(E[θ]).
In a Bayesian model, the deviance is random variable and the expected deviance under the
posterior distribution is used as a measure of fit. Between two models, the model with a
lower DIC value is preferred.
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The WAIC is similar to the DIC but the effective number of parameters is calculated
differently. The WAIC is defined as
WAIC = D(E[θ]) + 2pW , (14)
where
pW =
n∑
i=1
{
E
[
(log p(yi|θ))2
]− E [log p(yi|θ)]2} .
The WAIC is interpreted in the same way as the DIC. That is, the lower the WAIC, the
more preferable the model. Between the DIC and the WAIC, Gelman et al. (2014) argue
that the WAIC is preferred.
We also use two measures to validate the out-of-sample performance of the models. The
first measure is the concordance correlation coefficient (CCC), which is used to measure the
agreement between two variables. The CCC is defined as (Lin, 1989):
CCC =
2ρσ1σ2
σ21 + σ
2
2 + (µ1 − µ2)2
. (15)
where ρ is the correlation between the observed values and the predicted values, σ1 and µ1
are the standard deviation and the mean of the observed values, respectively, and σ2 and µ2
are the standard deviation and the mean of the predicted values, respectively. The value of
the CCC ranges from −1 to 1 with a value of 1 indicating perfect agreement between the
predicted values and the observed values. Between two models, a higher CCC value means
a better model.
The second measure is the well-known residual standard error (RSE), which is defined as
RSE =
√√√√ 1
n
n∑
i=1
(yˆi − yi)2, (16)
where yi and yˆi represent the ith observed value and the ith predicted value, respectively.
Between two models, the model with a lower RSE value is better.
5.5 Results
Table 4 shows the DIC and the WAIC of fitting the four Beta regression models with different
link functions to the training dataset. If we look at the rows, we see that the performance
based on the five link functions is quite similar except for the Cauchy link. If we look at the
columns, we see that the BetaBYM model performs the best. In terms of DIC, the BetaBYM
model with the Cauchy link performs the best. In terms of WAIC, however, the BetaBYM
model with the log-log link is the best. However, the performance of the BetaBYM model
is quite similar for the first four link functions. Using the logit link function is not a bad
choice.
Table 5 show the out-of-sample performance of the models with different link functions
on the test set. In terms of the CCC, the BetaBYM model with the log-log link performs
the best because the corresponding CCC value is the highest among the 20 cases. In terms
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Table 4: In-sample performance of the models with different link functions.
Model Logit Probit Loglog Cloglog Cauchy
DIC
BetaReg -2103.82 -2102.92 -2101.53 -2104.36 -2109.25
BetaRE -2103.60 -2102.20 -2100.60 -2104.10 -2109.79
BetaBesag -2105.79 -2109.89 -2109.58 -2107.41 -2114.87
BetaBYM -2116.93 -2115.13 -2112.55 -2118.06 -2132.92
WAIC
BetaReg -2070.47 -2070.84 -2071.36 -2069.72 -2062.49
BetaRE -2070.60 -2071.07 -2071.56 -2069.88 -2063.02
BetaBesag -2077.25 -2081.93 -2083.42 -2077.41 -2069.28
BetaBYM -2089.08 -2091.05 -2091.60 -2088.89 -2087.56
Table 5: Out-of-sample performance of the models with different link functions.
Model Logit Probit Loglog Cloglog Cauchy
CCC
BetaReg 0.42846 0.42810 0.42749 0.42801 0.42138
BetaRE 0.42834 0.42790 0.42733 0.42786 0.42126
BetaBesag 0.45289 0.46855 0.47168 0.45622 0.44610
BetaBYM 0.48595 0.48954 0.49127 0.48584 0.47814
RSE
BetaReg 0.01380 0.01376 0.01371 0.01383 0.01412
BetaRE 0.01380 0.01376 0.01371 0.01383 0.01413
BetaBesag 0.01364 0.01352 0.01342 0.01367 0.01412
BetaBYM 0.01359 0.01352 0.01340 0.01367 0.01445
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(a) The basic Beta regression model.
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(b) The BetaRE model.
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(c) The BetaBesag model.
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(d) The BetaBYM model.
Figure 8: Scatter plots of the observed brand name drug claim rates and those predicted by
the four models with the log-log link function. The out-of-sample predictions are plotted as
blue dots, while the in-sample fitted values are plotted as black circles.
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of the RSE, the BetaBYM model with the log-log link is also the best as it has the lowest
RSE value.
Figure 8 shows the scatter plots of the observed brand name drug claim rates and the
predicted values produced by the four models with the log-log link function. From the four
scatter plots, we see that the predicted values of the four models are pretty similar. We
also see that all four models do not fit the large rates well. The highest predicted value is
around 0.25, while the largest observed value is around 0.41 (see Table 1). Figure 9 shows
the distributions of the brand name drug claim rates predicted by the four models with the
log-log link function across the triangular areas. The maps look quite similar and it is hard
to see the differences. In addition, these maps look similar to the map of the observed rates
shown in Figure 2(a).
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(d) The BetaBYM model.
Figure 9: Distributions of the brand name drug claim rates predicted by the four models
with the log-log link function.
Tables 6, 7, 8, and 9 show the fitted coefficients and hyperparameters of the four models
with the log-log link function. In particular, the tables show the mean, the standard devi-
ation, the 2.5% quantile, the median, and the 97.5% quantile of the estimated parameters.
From the 2.5% and the 97.5% quantiles, we get the 95% credibility intervals of the fitted
parameters. If we look at the credibility intervals of the fitted coefficients, we see that the
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Table 6: Coefficients and hyperparameters from fitting the basic Beta regression model with
the log-log link.
Mean Std 0.025 Q 0.5 Q 0.975 Q.
(Intercept) -0.554 0.106 -0.763 -0.554 -0.345
avgscore 0.061 0.027 0.009 0.061 0.113
VITA 0.003 0.001 0.001 0.003 0.006
A00900 0.004 0.010 -0.017 0.004 0.024
A02300 0.066 0.014 0.039 0.066 0.093
A03150 0.003 0.011 -0.018 0.003 0.025
A03230 -0.002 0.013 -0.027 -0.002 0.023
A18450 -0.044 0.013 -0.069 -0.044 -0.019
A18800 0.002 0.029 -0.055 0.002 0.060
A07230 -0.198 0.044 -0.285 -0.198 -0.111
A85770 0.012 0.011 -0.010 0.012 0.035
A11070 -0.234 0.103 -0.437 -0.234 -0.031
A11902 0.132 0.039 0.057 0.133 0.208
φ 388.740 27.220 337.310 388.040 444.170
Table 7: Coefficients and hyperparameters from fitting the Beta regression model with ran-
dom effects. The log-log link function was used.
Mean Std 0.025 Q 0.5 Q 0.975 Q.
(Intercept) -0.553 0.107 -0.763 -0.553 -0.344
avgscore 0.061 0.027 0.008 0.061 0.113
VITA 0.003 0.001 0.001 0.003 0.006
A00900 0.004 0.010 -0.017 0.004 0.024
A02300 0.066 0.014 0.039 0.066 0.093
A03150 0.003 0.011 -0.018 0.003 0.025
A03230 -0.002 0.013 -0.027 -0.002 0.023
A18450 -0.044 0.013 -0.069 -0.044 -0.019
A18800 0.002 0.029 -0.055 0.002 0.060
A07230 -0.198 0.045 -0.285 -0.198 -0.111
A85770 0.012 0.011 -0.010 0.012 0.035
A11070 -0.234 0.104 -0.438 -0.234 -0.030
A11902 0.133 0.039 0.057 0.133 0.208
φ 390.650 27.960 337.970 389.880 448.040
ψ1 30149.160 22026.050 5634.800 24634.420 87681.270
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Table 8: Coefficients and hyperparameters from fitting the BetaBesag model with the log-log
link.
Mean Std 0.025 Q 0.5 Q 0.975 Q.
(Intercept) -0.574 0.109 -0.788 -0.574 -0.361
avgscore 0.067 0.027 0.013 0.067 0.121
VITA 0.003 0.001 0.001 0.003 0.006
A00900 0.002 0.011 -0.018 0.002 0.023
A02300 0.065 0.014 0.037 0.065 0.093
A03150 0.004 0.011 -0.017 0.004 0.026
A03230 0.000 0.013 -0.025 0.000 0.025
A18450 -0.036 0.014 -0.064 -0.036 -0.007
A18800 -0.012 0.031 -0.074 -0.012 0.049
A07230 -0.215 0.048 -0.310 -0.215 -0.121
A85770 0.012 0.011 -0.011 0.012 0.034
A11070 -0.206 0.110 -0.421 -0.206 0.011
A11902 0.134 0.039 0.057 0.134 0.210
φ 411.830 31.980 350.770 411.430 476.320
ψ2 3483.030 5884.000 461.760 1839.520 16609.730
Table 9: Coefficients and hyperparameters from fitting the BetaBYM model with the log-log
link.
Mean Std 0.025 Q 0.5 Q 0.975 Q.
(Intercept) -0.580 0.111 -0.800 -0.580 -0.362
avgscore 0.071 0.028 0.016 0.071 0.126
VITA 0.003 0.001 0.001 0.003 0.006
A00900 0.001 0.011 -0.020 0.001 0.023
A02300 0.065 0.015 0.036 0.065 0.093
A03150 0.005 0.011 -0.017 0.005 0.026
A03230 0.002 0.013 -0.024 0.002 0.028
A18450 -0.031 0.014 -0.059 -0.031 -0.002
A18800 -0.021 0.031 -0.083 -0.021 0.041
A07230 -0.225 0.049 -0.321 -0.225 -0.128
A85770 0.011 0.012 -0.012 0.011 0.034
A11070 -0.195 0.114 -0.419 -0.196 0.028
A11902 0.135 0.040 0.056 0.135 0.213
φ 425.630 33.890 362.380 424.470 495.770
ψ1 6583.970 2917.140 2614.040 6021.720 13846.680
ψ2 1435.850 1101.810 384.650 1118.950 4360.820
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credibility intervals of avgscore, VITA, A02300, and A11902 contain only positive values.
This means that these variables tend to have positive impact on the responses, i.e., the
brand name drug claim rates.
From these tables, we also see two variables whose 95% credibility intervals contain only
negative values. The two variables are A07230 and A18450. From Table 3, we see that both
variables are related to education spending. Since the fitted coefficients of these two variables
are negative, the two variables tend to have negative impact on the brand name drug claim
rates.
Tables 7, 8, and 9 also show the estimated hyperparameters of the unstructured ran-
dom effects and the structured random effects. Note that the hyperparameters are precision
parameters that are inverse to the variance of the random effects. The higher the hyperpa-
rameter, the lower the variance of the random effects. In Table 7, we see that the estimated
hyperparameter ψ1 is very large. This means that the random effects component of the
model has a very small variance and does not contribute much to explain the variation of
the response variable.
In Table 8, we see that the fitted precision parameter ψ2 of the structured random effects
is much lower than the fitted ψ1 in Table 7. In Table 9, we see the same pattern that fitted
ψ2 is much lower than the fitted ψ1. This means that the structured random effects help
more than the unstructured random effects in terms of explaining the response variation.
In summary, the above results show that modeling the spatial effect improves the perfor-
mance of the Beta regression model. In addition, including unstructured random effects in
the model only improve the performance marginally. To further assess the comprehensive-
ness of our Beta regression models, we provide additional results using models suggested in
Duncan et al. (2016). See Appendix A for additional results.
6 Concluding Remarks
The healthcare sector in the U.S. is a large sector that generates about 20% of the country’s
gross domestic product. This significance of healthcare has motivated researchers to develop
enhanced tools and approaches to better understand the industry through healthcare ana-
lytics. According to the 2019 Predictive Analytics in Health Care Trend Forecast (Society of
Actuaries, 2019), predictive analytics is poised to reshape the healthcare industry by achiev-
ing three aims: improved patient outcomes, higher quality of care, and reduced costs. In
particular, McKinsey estimates that big data analytics can help the U.S. healthcare industry
to save more than $300 billion per year, where two thirds of that come from the reductions
of approximately 8% in national healthcare expenditures.
In this paper, we examined and demonstrated the use of Beta regression models to study
the utilization of brand name drugs in the U.S. in order to understand variability of the
brand name drug claim rates across different areas of the U.S.. We studied different Beta
regression models with and without spatial effects and fitted these models to public datasets
obtained from the CMS and the IRS. The numerical results show that Beta regression models
are able to fit the brand name drug claim rates well and modeling the spatial effects improves
the performance of the Beta regression models. We also find some significant variables that
help to explain the variation of the brand name drug claim rates across different areas. The
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methods and findings in this paper are useful for healthcare actuaries in their data analysis.
By reflecting the effect of prescription drug utilization, these models can be used to update
an insured’s risk score in a risk adjustment model. Specifically, healthcare actuaries can
incorporate the geographic variation in their models used to select preferred providers.
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A Additional results
Duncan et al. (2016) tested several alternative regression frameworks for predictive modeling
of health care costs. In particular, they tested multiple linear regression models, lasso,
multivariate adaptive regression splines (MARS), random forests, M5 decision trees, and
boosted trees. For details of these models, readers are referred to Duncan et al. (2016) and
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Table 10: Parameters and the R packages of the additional models.
Model R Package Parameters
Linear model lm Multiple linear regression without interactions
Lasso glmnet Gaussian family
MARS earth Interactions up to degree = 1;
Generalized Cross Validation penalty = 1
Random forests randomForest Number of trees = 100; minimum node size = 10
M5 decision trees Cubist Number of committees = 25
Boosted trees gbm Number of trees = 5000; Shrinkage = 0.01
Table 11: Out-of-sample prediction results of the additional models.
Model CCC RSE
Linear model 0.4129 0.0141
Lasso 0.0000 0.0154
MARS 0.4420 0.0143
Random forest 0.4657 0.0126
M5 decision tree 0.4330 0.0131
Boosted trees 0.4658 0.0133
the references therein. In this section, we present the out-of-sample prediction results of
these models.
Table 10 shows the parameters and R packages we used to test the additional models.
Table 11 shows the out-of-sample prediction results obtained by these models. Figure 10
shows the scatter plots of the observed brand name drug claim rates and the predicted
values by the additional models. The variables input to these models are the same as those
selected for the Beta regression models described in Table 3.
From Table 11, we see that the lasso model produced the worst result. The reason is
that the lasso regression model produced an intercept-only model for the data. Figure 10(b)
also confirms this as the predicted values are constant. Comparing Tables 5 and 11, we
see that all these models do not perform better than the Beta regression model in terms
of CCC. However, the tree-based models (i.e., random forests, M5 decision trees, boosted
trees) produced lower RSE than the Beta regression model.
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(a) The linear regression model.
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(b) The lasso model.
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(c) The MARS model.
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(d) The random forests model.
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(e) The M5 decision trees model.
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(f) The boosted trees model.
Figure 10: Scatter plots of the observed brand name drug claim rates and those predicted
by the additional models.
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